In this review:
Factors predicting clinically significant PC in PIRADS 4 lesions
Imipramine delays clinical progression of PC
Little shared decision-making in PSA screening in the US
Repeat partial gland ablation safe with promising efficacy
Sedation an option for older, frail patients undergoing TURB
Excellent long-term outcomes in men with delayed PSA failure after prostatectomy
Delays in treatment during the COVID-19 pandemic in the US
Trends in survival for men with de novo metastatic PC
Selective radical prostatectomy in grade group 1 disease
More than half of men do not recover testosterone levels after ADT
Non-ADT MDT may delay disease progression in solitary oligo-recurrent cancer
Please login below to download this issue (PDF)